Skip to Content

    Over the past year, Hengrui, China’s largest pharma company, has received half-a-dozen approvals from the FDA, giving global sales at the generic- and innovative-drugs manufacturer a boost—and increasing confidence at home, where drug-contamination scares have left patients skeptical about the industry. Revenue in the first half of 2018 grew 22%, to $1.12 billion. Hengrui is also China’s market leader in oncological treatments, where demand is growing fast as the population grays. Its new-drug pipeline should help growth average 26% over the next two years.

    Company Information

    Overall Score3.4
    Sector
    Health Care
    Industry
    Pharmaceuticals
    CEO
    Zhou Yun Shu
    Websitehttp://www.hrs.com.cn
    Employees14,864
    HQ Location
    Lianyungang, China
    Revenues ($M) (Past 12 Months)$2,305
    Profits ($M) (Past 12 Months)$547
    Market Value as of Oct. 10, 2018 ($M)$30,922